The U.S. Senate is considering a bipartisan bill intended to speed up the development of genetically targeted drugs for patients with rare life-threatening or debilitating conditions.The Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030) would “allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor’s previously approved targeted drugs.”

The U.S. Senate is considering a bipartisan bill intended to speed up the development of genetically targeted drugs for patients with rare life-threatening or debilitating conditions.The Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030) would “allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor’s previously approved targeted drugs.”